Kiadis Pharma B.V. , a clinical stage biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, today announces that its lead product ATIR has been granted Orphan Drug Designation by the European Medicines Agency for the treatment of acute myeloid leukemia . Kiadis Pharma has previously been granted an ODD for ATIR by both the EMA and the FDA for the prevention of acute Graft versus Host Disease following an allogeneic bone marrow transplantation.
http://ift.tt/1zhKB16
http://ift.tt/1zhKB16
No comments:
Post a Comment